What is the recommended treatment for oral and vaginal candidiasis (thrush)?

Treatment for Oral and Vaginal Thrush

For oral thrush, use topical clotrimazole troches (10 mg 5 times daily) or miconazole buccal tablets (50 mg once daily) for mild disease, and oral fluconazole (100-200 mg daily) for moderate-to-severe disease for 7-14 days; for vaginal candidiasis, topical azoles are equally effective as oral fluconazole 150 mg single dose, though oral therapy shows marginally higher cure rates. 1, 2

Oral Candidiasis (Thrush)

Mild Disease

• First-line options:

  • Clotrimazole troches 10 mg 5 times daily for 7-14 days, OR
  • Miconazole mucoadhesive buccal tablet 50 mg applied to mucosal surface over canine fossa once daily for 7-14 days 1

• Alternative topical agents:

  • Nystatin suspension (100,000 U/mL) 4-6 mL 4 times daily, OR
  • Nystatin pastilles (200,000 U each) 1-2 pastilles 4 times daily for 7-14 days 1

Moderate-to-Severe Disease

• Oral fluconazole 100-200 mg daily for 7-14 days (strong recommendation; high-quality evidence) 1

Fluconazole-Refractory Disease

When initial fluconazole therapy fails:

• First alternatives:

  • Itraconazole solution 200 mg once daily, OR
  • Posaconazole suspension 400 mg twice daily for 3 days, then 400 mg daily for up to 28 days 1

• Second alternatives:

  • Voriconazole 200 mg twice daily, OR
  • Amphotericin B deoxycholate oral suspension 100 mg/mL 4 times daily 1

• Severe refractory cases requiring IV therapy:

  • Echinocandins (caspofungin 70 mg loading, then 50 mg daily; micafungin 100 mg daily; or anidulafungin 200 mg loading, then 100 mg daily), OR
  • IV amphotericin B deoxycholate 0.3 mg/kg daily 1

Special Considerations

• Denture-related candidiasis: Disinfect dentures in addition to antifungal therapy 1
• HIV-infected patients: Antiretroviral therapy is essential to reduce recurrent infections 1
• Recurrent infections: If chronic suppression needed, use fluconazole 100 mg 3 times weekly (though usually unnecessary) 1

Esophageal Candidiasis

Systemic therapy is always required—a diagnostic trial of antifungal therapy is appropriate before endoscopy 1

• First-line: Oral fluconazole 200-400 mg (3-6 mg/kg) daily for 14-21 days 1

• If unable to tolerate oral therapy:

  • IV fluconazole 400 mg (6 mg/kg) daily, OR
  • Echinocandin (micafungin 150 mg daily, caspofungin 70 mg loading then 50 mg daily, or anidulafungin 200 mg daily) 1
  • De-escalate to oral fluconazole once patient can tolerate oral intake 1

• Fluconazole-refractory esophageal disease:

  • Itraconazole solution 200 mg daily, OR
  • Voriconazole 200 mg (3 mg/kg) twice daily (IV or oral) for 14-21 days 1

Vulvovaginal Candidiasis

Uncomplicated VVC

Topical azoles and oral fluconazole are both highly effective (>75% cure rates), but single-dose oral fluconazole 150 mg shows marginally superior early clinical cure rates compared to topical therapy 2

• Oral option: Fluconazole 150 mg single dose

  • Network meta-analysis shows this has the best chance of achieving early (SUCRA=74.1%) and late (SUCRA=84.2%) mycological cure 2

• Topical options: Multiple azole formulations available (clotrimazole, miconazole, terconazole, butoconazole)—no single agent is superior 1

  • Single-day or multiple-day regimens are equally effective 2

The 2025 global guideline acknowledges that ibrexafungerp and oteseconazole now complement the antifungal armamentarium for superficial candidiasis 3, though specific dosing recommendations await further clinical data.

Recurrent VVC (≥4 episodes per year)

Two-phase approach is essential:

1. Induction phase:

   • Topical azole for 10-14 days, OR
   • Oral fluconazole for 10-14 days 1

2. Maintenance phase:

   • Fluconazole 150 mg once weekly for at least 6 months (achieves control in >90% of patients) 1, 4
   • Alternative: Clotrimazole cream 200 mg twice weekly or clotrimazole vaginal suppository 500 mg once weekly 1
   • Expect 40-50% recurrence rate after cessation of maintenance therapy 1

Non-albicans VVC

C. glabrata presents a treatment challenge:

• Determine if true infection versus colonization 1
• Azole therapy (including voriconazole) frequently unsuccessful 1
• Alternative regimens:
  • Boric acid 600 mg in gelatin capsules intravaginally daily for 14 days (must be compounded) 1
  • Nystatin intravaginal suppositories 1
  • Topical 17% flucytosine cream alone or combined with 3% amphotericin B cream 1

C. krusei: Responds to all topical antifungal agents 1

Critical Pitfalls to Avoid

1. Don't use chronic suppressive therapy for oral candidiasis routinely—it's usually unnecessary unless recurrent infections documented 1

2. Don't assume all vaginal Candida requires treatment—particularly C. glabrata may represent colonization rather than infection 1

3. Don't forget to address underlying risk factors:

   • Poor oral hygiene, denture hygiene 3, 1
   • Uncontrolled diabetes 3
   • HIV disease requiring antiretroviral therapy 1
   • Immunosuppressive medications (IL-17 inhibitors increase risk) 3

4. Consider antifungal resistance patterns:

   • The 2025 global guideline emphasizes emerging resistance, particularly C. auris 3
   • Fluconazole resistance must be considered when selecting therapy 3
   • C. glabrata and C. krusei have intrinsic azole resistance patterns 1

5. For esophageal candidiasis, don't delay systemic therapy—topical agents are insufficient 1

Pregnancy Considerations

While the guidelines provided focus primarily on non-pregnant populations, the evidence notes that longer courses of topical azole therapy may be needed during pregnancy 4. Oral fluconazole should be avoided in pregnancy due to teratogenic concerns, making topical azoles the preferred approach.